Prevalence of Hidradenitis Suppurativa
JAMA Dermatology · 01.10.2025 · 161 (10) · 1022
DOI: 10.1001/jamadermatol.2025.2373 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.10.2025. Verfasst von Dorra Bouazzi und 59 weiteren Autor:innen. Beteiligte Einrichtung: PHOENIX Center, Department of Allergy, Dermatology and Venereology, Herlev-Gentofte Hospital, Gentofte, Denmark. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a substantial burden. Standardized global prevalence estimates and data on associated sociodemographic and risk factors are lacking.
Objective
To estimate the global prevalence of HS and study differences in prevalence by age, sex, geographical location, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), smoking status, gross domestic product (GDP), and Human Development Index (HDI). Data Sources and Study Selection Included studies were conducted using the standardized Global Hidradenitis Suppurativa Atlas methodology with finalized data collection before May 19, 2023. Studies were required to use a population-based sampling method and conduct clinical confirmation of HS diagnosis following a screening questionnaire. Data Extraction and Synthesis Data were independently extracted from relevant studies by 2 reviewers (D.B. and C.E.M.) using a standardized form. Extracted variables included geographic location, age, sex, BMI (median and BMI >30), smoking status, HS prevalence estimates (with 95% CIs), GDP, and HDI. A proportional meta-analysis using a random-effects model was conducted on the included studies. Main Outcomes and Measures The primary outcome was the point prevalence of HS, confirmed by clinical examination. Secondary outcomes included differences in HS prevalence by sex, age, BMI category, smoking status, and country-level socioeconomic indicators (GDP and HDI). All outcomes were prespecified before data analysis.
Results
The sample included 22 743 participants, identifying 247 patients with HS, across 25 studies in 23 countries spanning 6 continents. The median proportion of female patients with HS was 55.6%, and the median age was 34.5 years. While the prevalence estimates showed considerable inconsistency ( I 2 > 75%; τ 2 = 0.747), the overall random-effects global prevalence of HS was 0.99% (95% CI, 0.67%-1.46%). Female sex was the only factor observed to be associated with the prevalence estimates (β = 1.02; 95% CI, 1.01-1.03). Conclusions and Relevance In this meta-analysis, an estimated global prevalence of HS between 0.67% and 1.46% surpassed previous global estimates. Substantial global variations in HS prevalence were also observed. Female sex was the only factor associated with prevalence in this sample. Future studies assessing genetic, environmental, and etiological factors are warranted to explain the heterogeneity in prevalence.
Autor:innen und Institutionen
- PHOENIX Center, Department of Allergy, Dermatology and Venereology, Herlev-Gentofte Hospital, Gentofte, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
- Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
- Department of Dermatology, Holy Family Hospital, Berekum, Ghana.
- Dermatology Unit, The Trust Hospital, Accra, Ghana.
Zitieren
APA
Bouazzi, D., Nielsen, S. M., Hagan, P. G., Botvid, S., Hove, L. S., Prens, E. P., Christensen, R., Jemec, G. B. E., GHiSA Group, Knecht-Gurwin, K., Szepietowski, J. C., Anaba, E. L., Chehad, A. S., Zobiri, S., Serradj, A., Bhuiyan, M. S. I., Noor, T., Guillem, P., Parvizi, M. M., …, & Ibekwe, P. U. (2025). Prevalence of Hidradenitis Suppurativa. JAMA Dermatology, 161(10), 1022. https://doi.org/10.1001/jamadermatol.2025.2373
Vancouver
Bouazzi D, Nielsen SM, Hagan PG, Botvid S, Hove LS, Prens EP, et al. Prevalence of Hidradenitis Suppurativa. JAMA Dermatology. 2025;161(10):1022. doi:10.1001/jamadermatol.2025.2373
BibTeX
@article{Bouazzi2025,
author = {Bouazzi, Dorra and Nielsen, Sabrina M and Hagan, Paa G and Botvid, Sofia and Hove, Lone S and Prens, Errol P and Christensen, Robin and Jemec, Gregor B E and GHiSA Group, GHiSA Group and Knecht-Gurwin, Klaudia and Szepietowski, Jacek C and Anaba, Ehiaghe L and Chehad, Ahmed S and Zobiri, Samira and Serradj, Amina and Bhuiyan, Mohammed S I and Noor, Towhida and Guillem, Philippe and Parvizi, Mohammad M and Saki, Nasrin and Alpsoy, Erkan and Vardar, Caner and Kanni, Theodora and Giamarellos-Bourboulis, Evangelos J and Frew, John W and Al Maharbi, Waleed H A and van Huijstee, Johanna C and Aarts, Pim and Dewi, Shinta T and Febriana, Sri A and Indrastuti, Niken and Suryawati, Nyoman and Pangastuti, Miranti and Adji, Aryani and Akhyar, Gardenia and Nopriyati, Nopriyati and Hazlianda, Cut P and Reyes-Baraona, Francisco and Matas, Carlos and Saeed, Haroon and Moodley, Ameshin and Binamer, Yousef and Kamil, Moonyza A A and Jocic, Ivana and Mijuskovic, Zeljko and Mallawaarachchi, Kanchana and Gangani, Chathurika and Tusheva, Ivana and Boshkovski, Vesna B and Hu, Danchen and Geng, Songmei and Medianfar, Cecilia E and Saunte, Ditte M L and Chandran, Nisha S and van der Zee, Hessel H and Zouboulis, Christos C and Benhadou, Farida and Villumsen, Bente and Alavi, Afsaneh and Ibekwe, Perpetua U},
title = {Prevalence of Hidradenitis Suppurativa},
journal = {JAMA Dermatology},
year = {2025},
volume = {161},
number = {10},
pages = {1022},
doi = {10.1001/jamadermatol.2025.2373}
}
EUVIMED